U.S. Luxury Stock News

NasdaqGS:IFRX
NasdaqGS:IFRXBiotechs

InflaRx (IFRX): Assessing Valuation After Positive Phase 2a Results for INF904 in HS and CSU

InflaRx (NasdaqGS:IFRX) released positive topline results from its Phase 2a basket study evaluating INF904 in hidradenitis suppurativa and chronic spontaneous urticaria. The company reported rapid and consistent clinical improvements as well as a favorable safety profile, fueling investor interest. See our latest analysis for InflaRx. Investors have taken notice of InflaRx’s momentum recently, especially after the promising Phase 2a results. The company’s 1-week share price return of 33% and...